CMS denies coverage for VNS Therapy depression indication
This article was originally published in The Gray Sheet
Executive Summary
Medicare agency issues national noncoverage determination for Cyberonics' VNS Therapy vagus nerve stimulation implant for treatment resistant depression (TRD) on May 4. The action follows a Feb. 5 noncoverage proposal (1"The Gray Sheet" Feb. 12, 2007, p. 10). The agency "has determined that there is sufficient evidence to conclude that vagus nerve stimulation is not reasonable and necessary for treatment resistant depression," CMS says. Last July, Cyberonics had requested coverage for TRD patients who either have been previously treated with or have refused treatment with electroconvulsive therapy, or have been previously hospitalized for depression. As a result of the depression reimbursement setback, Cyberonics has elected to refocus on its core business - which is centered on VNS Therapy's epilepsy indication...
You may also be interested in...
LivaNova Launches RECOVER Trial Of VNS For Depression To Meet CMS CED Requirement
LivaNova's RECOVER trial will randomize about 1,000 patients with treatment-resistant depression to either LivaNova’s vagus nerve stimulation therapy or a sham therapy and follow them for at least a year.
Neurotechnology Needs Better Outcome Measures, Diagnostics – VC Investors
The development and regulatory approval of new drugs and devices for treating diseases of the brain is hindered by the inadequacy of existing diagnostics and outcome measures, according to venture capitalists who spoke at a recent neurotech industry forum
Cyberonics Refocuses Sales And Marketing Effort On Epilepsy Treatment
Cyberonics will emphasize the epilepsy indication of its VNS vagus nerve stimulation implant in the wake of reimbursement difficulties that have hindered marketing of its depression indication